Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

objective response rate

the total proportion of patients with complete response (CR) and partial response (PR)

Time frame: every 6 weeks from the day of the first cycle of induction chemotherapy treatment (each cycle is 21 days) and every 8 weeks from the day of the first cycle of maintenance treatment (each cycle is 28 days) to 18 months after last patient's enrollment

progression-free survival

the total proportion of patients with no progression from date of the first day of treatment to the date of confirmed progressive disease or death which one occurs first

Time frame: from the day of the first cycle of treatment to the date of confirmed progressive disease or death, whichever occurs first after last patient's enrollment (each cycle is 21 days for induction treatment, and 28 days for maintenance treatment)

overall survival

from date of first day of treatment to the date of death by any cause

Time frame: from date of the first cycle of treatment to the date of death from any cause (each cycle is 21 days for induction treatment, and 28 days for maintenance treatment)

incidence and relationship with study drugs of grade 3-4 adverse events

the incidence and relationship with study drugs of grade 3 or 4 adverse events (based on NCI CTC-AE v5.0)

Time frame: from the date of the first cycle of treatment to 24 months after last patient's enrollment (each cycle is 21 days for induction treatment, and 28 days for maintenance treatment)